Endocytic receptor for pro-coagulant factor VIII: relevance to inhibitor formation.
The immunogenicity of therapeutic factor VIII (FVIII) in patients with haemophilia A remains a critical issue in patient management. This review describes the immunological processes involved in the activation of the immune system against FVIII, with a particular focus on the role of endocytic receptors for the recognition of FVIII by antigen-presenting cells.
Navarrete
Ana-Maria
AM
Sébastien Lacroix-Desmazes, INSERM UMR 872 Equipe 16, Centre de Recherche des Cordeliers, Paris, F-75006 France.
Dasgupta
Suryasarathi
S
Teyssandier
Maud
M
Repesse
Yohann
Y
Delignat
Sandrine
S
André
Sébastien
S
Bayry
Jagadeesh
J
Kaveri
Srinivas V
SV
Lacroix-Desmazes
Sébastien
S
D000906:Antibodies / Q000097:blood*; D000938:Antigen-Presenting Cells / Q000276:immunology* / Q000378:metabolism; D001777:Blood Coagulation; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D003029:Coagulants / Q000008:administration & dosage / Q000276:immunology* / Q000378:metabolism; D004705:Endocytosis; D005169:Factor VIII / Q000008:administration & dosage / Q000276:immunology* / Q000378:metabolism; D006467:Hemophilia A / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D011956:Receptors, Cell Surface / Q000378:metabolism*
D000906:Antibodies; D003029:Coagulants; D011956:Receptors, Cell Surface; D005169:Factor VIII